DNTH (Dianthus Therapeutics) YoY EBITDA Growth : -3.69% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Dianthus Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 was -3.69%.

Dianthus Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $-0.90.

Dianthus Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Dianthus Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics YoY EBITDA Growth Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

YoY EBITDA Growth

-125.93

-365.06

67.18

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
YoY EBITDA Growth	Get a 7-Day Free Trial						-20.75	-34.70	18.25	78.31	-3.69

Dianthus Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Dianthus Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (A: Dec. 2024 )
=	(EBITDA per Share (A: Dec. 2024 )	-	EBITDA per Share (A: Dec. 2023 ))	/	\| EBITDA per Share (A: Dec. 2023 ) \|
=	(-3.045	-	-9.278)	/	\| -9.278 \|
=	67.18 %

Dianthus Therapeutics's YoY EBITDA Growth for the quarter that ended in Dec. 2024 is calculated as:

	YoY EBITDA Growth (Q: Dec. 2024 )
=	(EBITDA per Share (Q: Dec. 2024 )	-	EBITDA per Share (Q: Dec. 2023 ))	/	\| EBITDA per Share (Q: Dec. 2023 )) \|
=	(-0.899	-	-0.867)	/	\| -0.867 \|
=	-3.69 %

Dianthus Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Dianthus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

N/A

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.